Pricing Log in Create free account
Friday 6 November 2026 Export DGX’s income statement to Excel — free account

Quest Diagnostics Incorporated

DGX Healthcare Diagnostics & Research

Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.

Revenue
+9.98%
EPS
+29.4%
Free cash flow
+6.21%
Total debt
−2.20%

Quarter to September 2026, against a year earlier

253.32 1.42 −0.56%
Market cap
$28.0B
P/E
25.0×
Fwd P/E
24.4×
Dividend yield
1.33%
F-score
8/9
Altman Z
3.15
Beneish M
−2.65
Dividend safety
85/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Quest Diagnostics Incorporated 10-Q filed Oct 21, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 6:31 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 23, 2025: 5 added · 1 removed · 32 modified; 41 with only figures updated; 2 moved without change

  1. Added · Acquisition of select clinical testing assets of Spectra Laboratories

    On August 4, 2025, we acquired select clinical testing assets of Fresenius Medical Care's wholly-owned Spectra Laboratories in an all-cash transaction for $34 million. The acquired business is included in our DIS business. See Note 5 to the interim unaudited consolidated financial statements for further discussion.